Bihua Chen bought $8.1M of BioAge Labs (BIOA)
Executed Sep 27 2024, disclosed Oct 1 2024, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Oct 1 2024), the stock returned +20.0% (delay-adjusted); from the execution session (Sep 27 2024), +24.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Bihua Chen (Other) filed 3 Form 4 reports in the trailing twelve months (2 purchases, 1 sale), most often in Aardvark Therapeutics, Inc. (AARD). Across 1 priced purchase filing, the average 21-session return was +39.0% from execution and +39.0% from disclosure (delay-adjusted; derived). The largest single filing was $8.0M of HLXC (800,000 sh × $10.00, as filed), executed Jan 26.
Healthcare · BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→